bluebird bio Revenue and Competitors
Estimated Revenue & Valuation
- bluebird bio's estimated annual revenue is currently $53.6M per year.
- bluebird bio received $632.5M in venture funding in July 2018.
- bluebird bio's estimated revenue per employee is $74,411
- bluebird bio's total funding is $484M.
- bluebird bio's current valuation is $612M. (January 2022)
Employee Data
- bluebird bio has 721 Employees.
- bluebird bio grew their employee count by 6% last year.
bluebird bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | SVP Marketing, Sales, Strategy and Analytics | Reveal Email/Phone |
3 | Head, US Business | Reveal Email/Phone |
4 | VP Process, Data, and Manufacturing Sciences (Severe Genetic Diseases) | Reveal Email/Phone |
5 | VP Head Information Technology and Informatics | Reveal Email/Phone |
6 | SVP Quality | Reveal Email/Phone |
7 | VP, Commercial, Oncology | Reveal Email/Phone |
8 | VP, Analytical Development | Reveal Email/Phone |
9 | VP, Oncology Corporate Development | Reveal Email/Phone |
10 | VP, Chief Counsel, Severe Genetic Diseases | Reveal Email/Phone |
bluebird bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is bluebird bio?
We are leading the gene therapy revolution. Our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing - providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. We have a lot of energy, and it's not just the abundance of coffee that keeps us going. Find out what sparks our excitement and inspires us every day.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$484M
Total Funding
721
Number of Employees
$53.6M
Revenue (est)
6%
Employee Growth %
$612M
Valuation
N/A
Accelerator
bluebird bio News
Bluebird bio's beta thalassemia gene therapy treatment Zynteglo might have some grounds to support an anticipated high price point,...
Investment climate for publicly-traded biotech stocks poor; Despite recent layoffs, Bluebird Bio's cash position is weak; Bluebird Bio's revenue...
The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist...
bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R ...
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Ph ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $153.1M | 729 | 5% | N/A |
#2 | $207.3M | 733 | 5% | N/A |
#3 | $262.4M | 738 | 16% | N/A |
#4 | $75M | 740 | 19% | $618M |
#5 | $190M | 754 | 21% | N/A |
bluebird bio Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-04-21 | $30.0M | Undisclosed | ARCH Venture Partners, Third Rock Ventures | Article |
| 2012-07-26 | $60.0M | D | Deerfield Partners, RA Capital | Article |
| 2013-06-03 | $60.0M | D | Deerfield Partners, RA Capital | Article |
| 2014-12-17 | $150.0M | Undisclosed | Article | |
| 2015-06-25 | $575.0M | BofA Merrill Lynch | Article | |
| 2016-12-08 | $200.0M | Undisclosed | Goldman, Sachs & Co | Article |
| 2017-06-28 | $350.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2017-12-14 | $600.0M | Undisclosed | Multiple | Article |
| 2018-01-10 | $651.3M | Undisclosed | Multiple | Article |
| 2018-07-25 | $632.5M | Undisclosed | Multiple | Article |